Hypereosinophilic syndrome and suspected myeloid neoplasia in relapsed Hodgkin lymphoma during immune checkpoint inhibitor therapy: a rare case.
Classic Hodgkin lymphoma (cHL) generally has favorable outcomes with frontline ABVD chemotherapy; however, 15-30% of advanced-stage patients experience relapse. While PD-1 inhibitors like pembrolizumab have shown promise in relapsed/refractory cHL, immune-related adverse events remain incompletely characterized. We rep...